FDA Week - 02/08/2019

FDA Biologics/Biosimilars Staff Director Leah Christl Leaves For Amgen

By Beth Wang
February 1, 2019 at 6:53 PM
FDA’s Leah Christl, head of the agency’s biologics and biosimilars staff in the Office of New Drugs (OND), will leave FDA on Feb. 22, after 16 years of working with the agency, drug center director Janet Woodcock announced in an email to center staff on Friday (Feb. 1). Sarah Yim, the agency announced, will replace Christl as acting director. Christl will join Amgen as executive director of its Global Regulatory and R&D Policy group, Amgen confirmed to Inside Health Policy...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.